MEKK3 coordinates with FBW7 to regulate WDR62 stability and neurogenesis.
View/ Open
Date
2018-12-01ICR Author
Author
Xu, D
Yao, M
Wang, Y
Yuan, L
Hoeck, JD
Yu, J
Liu, L
Yeap, YYC
Zhang, W
Zhang, F
Feng, Y
Ma, T
Wang, Y
Ng, DCH
Niu, X
Su, B
Behrens, A
Xu, Z
Type
Journal Article
Metadata
Show full item recordAbstract
Mutations of WD repeat domain 62 (WDR62) lead to autosomal recessive primary microcephaly (MCPH), and down-regulation of WDR62 expression causes the loss of neural progenitor cells (NPCs). However, how WDR62 is regulated and hence controls neurogenesis and brain size remains elusive. Here, we demonstrate that mitogen-activated protein kinase kinase kinase 3 (MEKK3) forms a complex with WDR62 to promote c-Jun N-terminal kinase (JNK) signaling synergistically in the control of neurogenesis. The deletion of Mekk3, Wdr62, or Jnk1 resulted in phenocopied defects, including premature NPC differentiation. We further showed that WDR62 protein is positively regulated by MEKK3 and JNK1 in the developing brain and that the defects of wdr62 deficiency can be rescued by the transgenic expression of JNK1. Meanwhile, WDR62 is also negatively regulated by T1053 phosphorylation, leading to the recruitment of F-box and WD repeat domain-containing protein 7 (FBW7) and proteasomal degradation. Our findings demonstrate that the coordinated reciprocal and bidirectional regulation among MEKK3, FBW7, WDR62, and JNK1, is required for fine-tuned JNK signaling for the control of balanced NPC self-renewal and differentiation during cortical development.
Collections
Subject
Animals
Mice, Transgenic
Mice, Knockout
Humans
Mice
Rats
Rats, Sprague-Dawley
Microcephaly
MAP Kinase Kinase Kinase 3
Mitogen-Activated Protein Kinase 8
Cell Cycle Proteins
Microtubule-Associated Proteins
Nerve Tissue Proteins
Signal Transduction
Cell Differentiation
MAP Kinase Signaling System
Protein Binding
Phosphorylation
Female
Male
Neurogenesis
HEK293 Cells
Neural Stem Cells
F-Box-WD Repeat-Containing Protein 7
Language
eng
Date accepted
2018-11-27
License start date
2018-12-19
Citation
PLoS biology, 2018, 16 (12), pp. e2006613 - ?
Publisher
PUBLIC LIBRARY SCIENCE
Except where otherwise noted, this item's license is described
as
https://creativecommons.org/licenses/by/4.0
Related items
Showing items related by title, author, creator and subject.
-
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
Jamieson, D; Griffin, MJ; Sludden, J; Drew, Y; Cresti, N; et al. (ELSEVIER SCI LTD, 2016-11-01)PURPOSE: We performed a multi-centre phase I study to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the orally available small molecule mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, ... -
Ubiquitin-Mediated Regulation of RIPK1 Kinase Activity Independent of IKK and MK2.
Annibaldi, A; Wicky John, S; Vanden Berghe, T; Swatek, KN; Ruan, J; et al. (CELL PRESS, 2018-02-15)Tumor necrosis factor (TNF) can drive inflammation, cell survival, and death. While ubiquitylation-, phosphorylation-, and nuclear factor κB (NF-κB)-dependent checkpoints suppress the cytotoxic potential of TNF, it remains ... -
MK2 Phosphorylates RIPK1 to Prevent TNF-Induced Cell Death.
Jaco, I; Annibaldi, A; Lalaoui, N; Wilson, R; Tenev, T; et al. (CELL PRESS, 2017-06-01)TNF is an inflammatory cytokine that upon binding to its receptor, TNFR1, can drive cytokine production, cell survival, or cell death. TNFR1 stimulation causes activation of NF-κB, p38α, and its downstream effector kinase ...